New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors

Seminars in Oncology

Volumn 33, Issue 4, 2006, Pages 407-420

  Faivre, Sandrine ^a   Djelloul, Siham ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; MIDOSTAURIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ARTICLE; CANCER; CANCER INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BINDING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 33746544343     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.005     Document Type: Article

References (134)

1. Richter M., and Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol 24 (2005) 271-282
2. Schwarz J.K., and Yarbro J.W. Scientific basis of cancer chemotherapy. In: Perry M.C. (Ed). The Chemotherapy Source Book (ed 3) (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1-6
3. Bagshawe K.D. The history of targeted therapy for cancer, in K.K. S. In: Harrington K.J. (Ed). Targeted Therapy for Cancer (2003), Oxford University Press, New York, NY 3-16
4. Blay J.Y., Le Cesne A., Alberti L., et al. Targeted cancer therapies. Bull Cancer 92 (2005) E13-E18
5. Tibes R., Trent J., and Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 45 (2005) 357-384
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
7. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
8. Reynolds N.A., and Wagstaff A.J. Cetuximab. In the treatment of metastatic colorectal cancer. Drugs 64 (2004) 109-118
9. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
11. Nahta R., Hortobagyi G.N., and Esteva F.J. Growth factor receptors in breast cancer. Potential for therapeutic intervention. Oncologist 8 (2003) 5-17
12. Cohen M.H., Williams G.A., Sridhara R., et al. United States Food and Drug Administration Drug Approval summary. Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10 (2004) 1212-1218
13. Johnson J.R., Cohen M., Sridhara R., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11 (2005) 6414-6421
14. Johnson J.R., Bross P., Cohen M., et al. Approval summary. Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9 (2003) 1972-1979
15. Dagher R., Cohen M., Williams G., et al. Approval summary. Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8 (2002) 3034-3038
16. Cohen M.H., Williams G., Johnson J.R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (2002) 935-942
17. Ciardiello F., De Vita F., Orditura M., et al. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 16 (2004) 130-135
18. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2004) 21-26
19. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer. Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
20. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
21. King C.R., Kraus M.H., and Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229 (1985) 974-976
22. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
23. Seshadri R., Firgaira F.A., Horsfall D.J., et al., The South Australian Breast Cancer Study Group. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11 (1993) 1936-1942
24. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
25. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
26. Marmor M.D., Skaria K.B., and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58 (2004) 903-913
27. Raben D., Helfrich B., and Bunn Jr. P.A. Targeted therapies for non-small-cell lung cancer. Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 59 (2004) 27-38
28. Mechtersheimer G., Egerer G., Hensel M., et al. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 444 (2004) 108-118
29. Duensing A., Heinrich M.C., Fletcher C.D., et al. Biology of gastrointestinal stromal tumors. KIT mutations and beyond. Cancer Invest 22 (2004) 106-116
30. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy. focus on NSCLC. Int J Radiat Oncol Biol Phys 58 (2004) 991-1002
31. Leslie W.T., and Bonomi P.D. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am 18 (2004) 245-267
32. Beeram M., and Patnaik A. Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics. Hematol Oncol Clin North Am 16 (2002) 1089-1100
33. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
34. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (2004) 275-286
35. Board R., and Jayson G.C. Platelet-derived growth factor receptor (PDGFR). A target for anticancer therapeutics. Drug Resist Updat 8 (2005) 75-83
36. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18 (2004) 338-340
37. Liu W., Ahmad S.A., Reinmuth N., et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5 (2000) 323-328
38. Goldie J. Drug resistance. In: Perry M.C. (Ed). The Chemotherapy Source Book (ed 3) (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1-6
39. Cools J., Maertens C., and Marynen P. Resistance to tyrosine kinase inhibitors. Calling on extra forces. Drug Resist Updat 8 (2005) 119-129
40. Jain R.K. Normalization of tumor vasculature. An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
41. Lin M.I., and Sessa W.C. Antiangiogenic therapy. Creating a unique "window" of opportunity. Cancer Cell 6 (2004) 529-531
42. Johnston S.R. Clinical trials of intracellular signal transductions inhibitors for breast cancer-A strategy to overcome endocrine resistance. Endocr Relat Cancer 12 suppl 1 (2005) S145-S157
43. Gee J.M., Harper M.E., Hutcheson I.R., et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 (2003) 5105-5117
44. Sakamoto J.M. SU-11248 SUGEN. Curr Opin Invest Drugs 5 (2004) 1329-1339
45. Hotte S.J., and Hirte H.W. BAY 43-9006. Early clinical data in patients with advanced solid malignancies. Curr Pharm Des 8 (2002) 2249-2253
46. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388S-6392S
47. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
48. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
49. Vignot S., Faivre S., Aguirre D., et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
50. Dutcher J.P. Mammalian target of rapamycin inhibition. Clin Cancer Res 10 (2004) 6382S-6387S
51. Goekjian P.G., and Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10 (2001) 2117-2140
52. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
53. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
54. Herbst R.S., Takeuchi H., and Teicher B.A. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41 (1998) 497-504
55. Kakeji Y., and Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15 (1997) 39-48
56. Huber P.E., Bischof M., Jenne J., et al. Trimodal cancer treatment. Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65 (2005) 3643-3655
57. Inoue K., Chikazawa M., Fukata S., et al. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 9 (2003) 886-899
58. Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62 (2002) 5476-5484
59. Gasparini G. Metronomic scheduling. The future of chemotherapy?. Lancet Oncol 2 (2001) 733-740
60. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly. Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
61. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo. A role for altered tumor angiogenesis. Cancer Res 61 (2001) 5090-5101
62. Kumar R., Mandal M., Lipton A., et al. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2 (1996) 1215-1219
63. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance. Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004) 926-935
64. Argiris A., Wang C.X., Whalen S.G., et al. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10 (2004) 1409-1420
65. Knowlden J.M., Hutcheson I.R., Jones H.E., et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (2003) 1032-1044
66. Okubo S., Kurebayashi J., Otsuki T., et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 90 (2004) 236-244
67. Kitazaki T., Oka M., Nakamura Y., et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49 (2005) 337-343
68. Yanase K., Tsukahara S., Asada S., et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3 (2004) 1119-1125
69. Stewart C.F., Leggas M., Schuetz J.D., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64 (2004) 7491-7499
70. Nakamura Y., Oka M., Soda H., et al. Gefitinib ("Iressa," ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65 (2005) 1541-1546
71. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
72. Hemstrom T.H., Joseph B., Schulte G., et al. PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp Cell Res 305 (2005) 200-213
73. Boulay A., Rudloff J., Ye J., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11 (2005) 5319-5328
74. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
75. She Q.B., Solit D., Basso A., and Moasser M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9 (2003) 4340-4346
76. Bianco R., Shin I., Ritter C.A., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22 (2003) 2812-2822
77. deGraffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10 (2004) 8059-8067
78. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer. A phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
79. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer. A phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
80. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
81. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer. How do we go from INTACT to impact?. J Clin Oncol 22 (2004) 759-761
82. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
83. Aguirre D., Boya P., Bellet D., et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9 (2004) 797-805
84. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
85. Punt C.J., Boni J., Bruntsch U., et al. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14 (2003) 931-937
86. Rudloff J., Boulay A., Zumstein-Mecker S., et al. The mTOR pathway in estrogen response. A potential for combining the rapamycin derivative RAD001 wih the aromatase inhibitor letrozole (Femara) in breast carcinoma. Proc Am Assoc Cancer Res 45 (2004) 1298 (abstr 5619)
87. Luo Y., Marx S.O., Kiyokawa H., et al. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 16 (1996) 6744-6751
88. van Oosterom A., Dumez H., Desai J., et al. A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc Am Assoc Cancer Res 45 (2004) 694 (abstr 3002)
89. Newton A.C. Protein kinase C. Structure, function, and regulation. J Biol Chem 270 (1995) 28495-28498
90. Nishizuka Y. The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. JAMA 262 (1989) 1826-1833
91. Gutcher I., Webb P.R., and Anderson N.G. The isoform-specific regulation of apoptosis by protein kinase C. Cell Mol Life Sci 60 (2003) 1061-1070
92. Hug H., and Sarre T.F. Protein kinase C isoenzymes. Divergence in signal transduction?. Biochem J 291 (1993) 329-343
93. Blumberg P.M., Acs G., Areces L.B., et al. Protein kinase C in signal transduction and carcinogenesis. Prog Clin Biol Res 387 (1994) 3-19
94. Caponigro F., French R.C., and Kaye S.B. Protein kinase C. A worthwhile target for anticancer drugs?. Anticancer Drugs 8 (1997) 26-33
95. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 142 (2001) 1-96
96. Mackay H.J., and Twelves C.J. Protein kinase C. A target for anticancer drugs?. Endocr Relat Cancer 10 (2003) 389-396
97. Monnerat C., Henriksson R., Le Chevalier T., et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15 (2004) 316-323
98. Lyseng-Williamson K., and Jarvis B. Imatinib. Drugs 61 (2001) 1765-1774
99. Croom K.F., and Perry C.M. Imatinib mesylate. In the treatment of gastrointestinal stromal tumours. Drugs 63 (2003) 513-522
100. Sawaki A., and Yamao K. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors-A review. Cancer Chemother Pharmacol 54 suppl 1 (2004) S44-S49
101. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib. randomised trial. Lancet 364 (2004) 1127-1134
102. Lee C.P., Attard G., Poupard P.D., et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 23 (2005) 3054a (abstr)
103. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4 (2005) 677-685
104. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
105. Naoe T., and Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 61 (2004) 2932-2938
106. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 (2005) 1028-1043
107. Olson J.M., and Hallahan A.R. p38 MAP kinase. A convergence point in cancer therapy. Trends Mol Med 10 (2004) 125-129
108. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
109. Heim M., Scharifi M., Zisowsky J., et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16 (2005) 129-136
110. Ratain MJ, Eisen T, Stadler WM, et al: Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
111. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
112. Posada EM, Gulley J, Arlen PM, et al: A phase II study of BAY 43-9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling. (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
113. Siu LL, Winquist E, Agulnik M, et al: A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). (abstr 5566) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
114. Flaherty KT, Redlinger M, Schuchter LM, et al: Phase I/II pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. (abstr 3037) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
115. Adjei AA, Mandrekar S, Marks RS, et al: A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). (abstr 3067) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
116. Eisen T, Ahmad T, Gore ME, et al: Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. (abstr 7508). American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
117. Steinbild S, Baas F, Gmehling D, et al: Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. (abstr 3115) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
118. Osusky K.L., Hallahan D.E., Fu A., et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7 (2004) 225-233
119. Abrams T.J., Lee L.B., Murray L.J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
120. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
121. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20 (2003) 757-766
122. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
123. Schueneman A.J., Himmelfarb E., Geng L., et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63 (2003) 4009-4016
124. Data on file. Pfizer Inc, New York, NY, 2005
125. Putzer B.M., and Drosten M. The RET proto-oncogene. a potential target for molecular cancer therapy. Trends Mol Med 10 (2004) 351-357
126. Ichihara M., Murakumo Y., and Takahashi M. RET and neuroendocrine tumors. Cancer Lett 204 (2004) 197-211
127. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5 (2005) 367-375
128. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2 (2003) 1011-1021
129. Faive S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and first evidence of antitumor activity of sunitinib, a novel oral multi-target tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
130. Demetri DG, van Oosterom A, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17 2005. Available at: www.asco.org
131. Motzer R, Rini BI, Michaelson M, et al: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
132. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
133. Miller KD, Burstein HJ, Elias AD, et al: Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org
134. Kulke M, Lenz HJ, Meropol NJ, et al: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). (Oral presentation) American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005. Available at: www.asco.org